

Organic & Biomolecular Chemistry

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

Palladium-catalyzed carbonylation of halo arene-*cis*-dihydrodiols to the corresponding carboxylates. Access to compounds unavailable by toluene dioxygenase-mediated dihydroxylation of the corresponding benzoate esters

Jordan Froese, Jason Reed Hudlicky and Tomas Hudlicky*

Chemistry Department and Centre for Biotechnology, Brock University, 500 Glenridge Avenue, St. Catharines, Ontario L2S 3A1, Canada.

E-mail: thudlicky@brocku.ca

The authors wish to dedicate this paper to the memory of David Gibson (deceased July 24, 2014) and in recognition of his lifetime contributions to the field of biocatalysis.

Abstract

A series of arene-*cis*-dihydrodiol carboxylates was prepared by palladium-catalyzed carbonylation of (1*S*, 2*S*-*cis*)-3-iodo-3,5-cyclohexadiene-1,2-diol, which is obtained in high titers by enzymatic dihydroxylation of iodobenzene. Both the free diol and the corresponding acetonide were subjected to this protocol to produce various arene-*cis*-dihydrodiol carboxylates that are unavailable by fermentations of the corresponding benzoates or are produced in low yields. The comparison of yields obtained from fermentations versus carbonylation was made for all compounds investigated. Experimental and spectral data are provided for all new compounds.

Introduction

The enzymatic dihydroxylation of aromatic compounds to the corresponding arene-*cis*-dihydrodiols such as **1**, Figure 1, was discovered by Gibson in 1968.¹ In the last 25 years many new metabolites resulting from this enzymatic oxidation were discovered and catalogued² and used in enantioselective synthesis of natural products.³





Figure 1. Enzymatic dihydroxylation of arenes by toluene dioxygenase (TDO).

The diols derived from single ring aromatics and various benzoate esters are available in multigram quantities by fermentation with recombinant organisms such as *E. coli* JM109 (pDTG601A), which overexpresses toluene dioxygenase. This organism, and others, expressing related dioxygenases for dihydroxylation of fused aromatics or biphenyls, were also developed by Gibson in 1989.⁴

The yields of arene-*cis*-dihydrodiols vary from milligrams/L to 30 or more grams/L. Whole-cell fermentation of aromatics with the JM109 clone was investigated at medium scales (10 to 15L fermentors) for several common substrates.⁵ In addition, a procedure was published in *Organic Syntheses*⁶ for the preparation of several halo arene-*cis*-dihydrodiols by employing the blocked mutant, *Pp39D*, and common equipment, such as is found in any laboratory engaged in organic synthesis. The most commonly used metabolites are shown in Table 1, along with the yields of fermentation.

Table 1. Comparison of yields of enzymatic dihydroxylation of various substrates.

Entry	R =	organism	Yield (g/L) or (%)	ee (%)	Reference
2	Me	<i>Pp39D</i>	0.93	-	1 ^b , 7, 8 ^c
		<i>PpUV4</i>	(~60%)	>98	9, 10 ^c
		JM109	12-15 [16] ^a	-	4, 5
3	F	<i>PpUV4</i>	-	~60	9 ^b , 10 ^c
4	Cl	<i>Pp39D</i>	0.3-1	-	1 ^b , 8, 11 ^c
		<i>PpUV4</i>	(80%)	>98	9, 10 ^c
		JM109	9-11 [12] ^a	-	5
5	Br	<i>Pp39D</i>	-	-	1, 12 ^b
		<i>PpUV4</i>	(77%)	>98	10 ^c , 13

		JM109	9-12 [20] ^a	-	5
6	I	<i>Pp39D</i>	-	-	1
		<i>PpUV4</i>	(85%)	>98	10 ^c , 13, 14 ^b
		JM109	7-9 [10] ^a	>98	5, 14 ^b
7	CH=CH ₂	<i>Pp39D</i>	(>95%)	>98	8 ^b , 15 ^c , 16
		<i>PpUV4</i>	(~30%)	>98	10 ^c
		JM109	6-8 [12] ^a	-	5
8	CCH	<i>Pp39D</i>	0.05	-	8 ^b
		<i>PpUV4</i>	(~10%)	>98	10 ^c
		JM109	3-3.5	-	5
9	CH ₂ CH ₂ OAc	JM109	3-5 [5] ^a	>98	5, 17 ^{b,c}
10	CH ₂ CH ₂ Br	<i>Pp39D</i>	0.2	96	18 ^{b,c}
		JM109	6-9 [9] ^a	-	5
11	CO ₂ Me	<i>Pp39D</i>	2.25	-	19 ^b
		JM109	1.3 [1.5] ^a	>98	20 ^c
12	CO ₂ Et	JM109	0.8 [1.0] ^a	>98	20 ^{bc} , 21
13	CO ₂ nPr	JM109	0.07	>98	20 ^{bc}
14	CO ₂ iPr	JM109	0.05	>98	20 ^{bc}
15	CO ₂ tBu	JM109	-	-	20 ^{bc}
16	CO ₂ CH ₂ CHCH ₂	JM109	0.6	>98	20 ^{bc}
17	CO ₂ CH ₂ CCH	JM109	1.0	>98	20 ^{bc}
18	CO ₂ CH ₂ (C ₆ H ₅) ^d	JM109	-	-	-
19	cyclopropyl	JM109	2.5 [8-10] ^a	>98	22 ^{b,c}

Legend: ^aCurrent yield on 10-15L scale as obtained in the Hudlicky group; ^breference to isolation, ^creference to full characterization, ^dAttempted fermentation of this ester, performed as part of this study, did not provide the diol metabolite.

From the Table it is clear that only a few substrates produce yields upward of 10 grams/L. Moreover, the recently investigated dihydroxylation of various benzoate esters (Me, Et, *n*-Pr, *i*-Pr, allyl, propargyl) revealed that these are poor substrates, as evidenced by the low yields of metabolites **11-17**.²⁰ This study was extended to dihydroxylation of

methyl halobenzoates²³ and, most recently, to various alkyl halobenzoates in order to compare regioselectivity of dihydroxylation as a function of both, halogen and alkoxy functionalities.²⁴

The diol derived from ethyl benzoate, **12**, was used in a very efficient synthesis of oseltamivir²¹ and its production at higher titers would be beneficial. For any future refinement of the published synthesis of oseltamivir and its derivatives the availability of **12** in larger amounts would be essential. In this paper we report a simple palladium-catalyzed carbonylation protocol for the preparation of various carboxylates from iodo- or bromoarene *cis*-dihydrodiols (entry **6** and **5**, respectively).

Results and discussion

Cross-coupling strategies have been used in order to obtain homochiral *cis*-diols that would not be available from the corresponding aromatic substrates. Thus Boyd prepared a number of compounds via cross-coupling of various vinyl halides derived from arene *cis*-dihydrodiols, in some cases with the diene unit being partially saturated (potassium azodicarboxylate (PAD) reduction).²⁵ Banwell successfully performed sp^2 - sp^3 cross-coupling of the vinyl iodide in diol **6** (protected as acetonide) at elevated temperatures without detriment to the otherwise labile diene functionality.²⁶ It is well known that the diene diols of type **1** are prone to stereoselective Diels-Alder type dimerization even at low temperatures, with the dimerization proceeding much faster when the diols are protected as their corresponding acetonides.²⁷ We have prepared dimers from the acetonide-protected diols **20**, **22** and **23**, namely the pentacyclic compounds **30**, **31** and **32**, shown in Figure 2, in order to assess their presence in the carbonylation reaction mixture.





Figure 2. Diels-Alder dimers produced from the acetonide-protected diols **20**, **22** and **23**

These compounds were prepared in reasonable yields (**30** = 38%, **31**, = 42%, **32** = 64%) by refluxing a solution of the corresponding acetonides in xylene for 24-40 hours. We investigated the palladium-catalyzed carbonylation with the acetonide-protected diol **20** (EtOH, 40 °C) and were delighted to find that ethyl ester **23** was produced with high conversions and good isolated yields at multigram scales, Scheme 1. The carbonylation of the bromo derivative **21** also yielded the corresponding ethyl ester **23**, although in lower yield than that obtained with the carbonylation of vinyl iodide **20**. As well, the free diols **6** and **5** were subjected to the same conditions. The carbonylation of **6** (EtOH, 40 °C) produced **12** in good yields, far exceeding those obtained from the biotransformation of ethyl benzoate, Table 2. The substrate scope was subsequently expanded, and the carbonylation procedure was utilized to produce the acetonide-protected compounds **22-29**, Table 2. Despite initial concerns, little or no dimerization was observed under the carbonylation reaction conditions.



Scheme 1

Both the free diol **6** and the acetonide-protected diol **20** were subjected to carbonylation in the presence of various alcohols, to produce ester derivatives which were previously obtained in low yields by fermentation.²⁰ Furthermore, it was previously shown that compound **15** was unavailable through biotransformation²⁰, and it was demonstrated, as part of this study, that compound **18** was similarly unavailable through biotransformation. Compounds **15** and **18**, as well as their corresponding acetonide-protected derivatives **26** and **29**, were accessed through the carbonylation of **6** and **20** respectively. The comparison of isolated yields is shown in Table 2.

Table 2. Comparison of the yields of benzoate metabolites obtained by fermentation with those from the carbonylation of free halodiene **6** or acetone **20**.

Entry	Yield of free diol by fermentations of benzoate (%) (g/L) ²⁰	Yield of benzoate by carbonylation of free diol 6 (%) (g/L) ^a	Entry	Yield of benzoate by carbonylation of acetone 20 (%) (g/L) ^b
11 R = Me	19.2% (1.3)	68% (6.8)	22 R = Me	68% (6.8)
12 R = Et	43.4% (0.8)	72% (7.2)	23 R = Et	73% (7.3)
13 R = <i>n</i> -Pr	5.8% (0.07)	62% (6.2)	24 R = <i>n</i> -Pr	64% (6.4)
14 R = <i>i</i> -Pr	4.1% (0.05)	72% (7.2)	25 R = <i>i</i> -Pr	76% (7.6)
15 R = <i>t</i> -Bu	-	17% (1.7)	26 R = <i>t</i> -Bu	10% (1.0)
16 R = allyl	52.0% (0.6)	7% (0.7)	27 R = allyl	27% (2.7)
17 R = CH ₂ CCH	69.1% (1.0)	36% (3.6)	28 R = CH ₂ CCH	22% (2.2)
18 R = benzyl	-	10% (1.0)	29 R = benzyl	71% (7.1)

^aHypothetical yield for comparison. Biotransformation of iodobenzene affords up to 10 g/L of diol **6**. This yield was multiplied by the yield of the subsequent carbonylation step to reflect the relative amount of compounds **11-18** available through this method. (Ex. 10 g/L (biotransformation yield of **6**) x 72% (carbonylation yield of **12**) = 7.2 g/L of compound **12**)

^bHypothetical yield for comparison. Biotransformation of iodobenzene affords up to 10 g/L of diol **6**. This yield was multiplied by the yield of the subsequent carbonylation step

to reflect the relative amount of compounds **22-29** available through this method. (Ex. 10 g/L (biotransformation yield of **6**) x 73% (carbonylation yield of **23**) = 7.3 g/L of compound **23**)

From Table 2, it is clear that the carbonylation of the readily available enzymatic metabolite, namely vinyl iodide **6**, provides a much more efficient access to esters **11-14**, **17**, **18** than would a direct fermentation of the corresponding benzoates. This is also true for the carbonylation of the acetonide-protected diol **20**, which provided efficient access to compounds **22-29**.

Conclusions

Palladium-catalyzed carbonylation of (1*S*, 2*S*-*cis*)-3-iodo-3,5-cyclohexadiene-1,2-diol, as well as its acetonide, in the presence of an appropriate alcohol led to the synthesis of various arene-*cis*-diol carboxylates that are not readily available by enzymatic dihydroxylation of the parent benzoate esters. The carbonylation protocol provided the known metabolites of alkyl benzoates in much higher yields than those obtained in fermentations. In addition, this protocol provided several new compounds previously unavailable by fermentation. The higher yields of benzoate-derived metabolites obtained by the carbonylation protocol will make it easier to provide improvements in the synthesis of oseltamivir analogs and other compounds derived from arene-*cis*-diol carboxylates. Finally, the combination of biocatalysis and traditional synthesis clearly provides a more effective access to compounds of interest; this has been articulated in several recent reviews.^{3c,3d,28}

Acknowledgements

The authors are grateful to the following agencies for financial support of this work: Natural Sciences and Engineering Research Council of Canada (NSERC) (Idea to Innovation and Discovery Grants), Canada Research Chair Program, Canada Foundation for Innovation (CFI), TDC Research, Inc., TDC Research Foundation, the Ontario


Partnership for Innovation and Commercialization (OPIC), and The Advanced Biomanufacturing Centre (Brock University).

The authors thank Melissa DiSanto, recipient of an NSERC Undergraduate Student Research Award 2014, for assistance with this project.

The authors thank Pavlína Horáková, a visiting exchange student from Palackeho University in Olomouc, Czech Republic for assistance on this project. Her visit was financed in part by a grant CZ.1.07/2.4.00/31.0130 from European Social Funds.


Experimental section

General procedure for the carbonylation of compound **6** to corresponding esters (**11-15**)




A solution of **6**¹⁰ (500 mg, 2.10 mmol) was dissolved in alcohol (30 mL), and carbon monoxide was bubbled through the reaction mixture for 15 minutes, after which triethylamine (0.59 mL, 4.2 mmol) was added followed by solid triphenylphosphine (110 mg, 0.42 mmol) and palladium (II) acetate (47 mg, 0.21 mmol). The orange suspension was heated to 40 °C. The reaction was monitored by TLC [hexanes/EtOAc (1:1)] and consumption of the starting material was observed after 1-2.5 hours. Upon cooling to room temperature, the crude reaction mixture was concentrated to dryness under reduced pressure. The residue was then dissolved in diethyl ether, filtered through a plug of Celite, and concentrated. The crude material was purified by flash column chromatography [hexanes/EtOAc (1:1)] to yield the corresponding ester.

General procedure for the carbonylation of compound 6 to corresponding esters (16-18)



A solution of **6**¹⁰ (500 mg, 2.10 mmol) was dissolved in a solution of THF/alcohol (9:1) (30 mL), and carbon monoxide was bubbled through the reaction mixture for 15 minutes, after which triethylamine (0.59 mL, 4.2 mmol) was added followed by solid triphenylphosphine (110 mg, 0.42 mmol) and palladium (II) acetate (47 mg, 0.21 mmol). The orange suspension was heated to 40 °C. The reaction was monitored by TLC [hexanes/EtOAc (1:1)] and consumption of the starting material was observed after 4-6 hours. Upon cooling to room temperature, the crude reaction mixture was concentrated to dryness under reduced pressure. The residue was then dissolved in diethyl ether, filtered through a plug of Celite, and concentrated. The crude material was purified by flash column chromatography [hexanes/EtOAc (1:1)] to yield the corresponding ester.


General procedure for the acetonide protection of compound 6 and subsequent carbonylation of compound 20 to corresponding esters (22-26)



A solution of **6**¹⁰ (500 mg, 2.10 mmol) was dissolved in 2,2-dimethoxypropane (10 mL), to which was added a catalytic amount of *p*-toluenesulfonic acid. The reaction was monitored by thin layer chromatography (TLC), and was observed to be complete after 0.5 hours. The reaction mixture was concentrated under reduced pressure, diluted with EtOAc (15 mL) and washed with a saturated solution of sodium bicarbonate (2 x 3 mL)

and brine (1 x 2 mL). The reaction mixture was concentrated under reduced pressure, and dissolved in alcohol (30 mL). Carbon monoxide was bubbled through the reaction mixture for 15 minutes, after which triethylamine (0.59 mL, 4.2 mmol) was added followed by solid triphenylphosphine (110 mg, 0.42 mmol) and palladium (II) acetate (47 mg, 0.21 mmol). The orange suspension was heated to 40 °C. The reaction was monitored by TLC [hexanes/EtOAc (4:1)] and consumption of the starting material was observed after 1-2.5 hours. Upon cooling to room temperature, the crude reaction mixture was concentrated to dryness under reduced pressure. The residue was then dissolved in diethyl ether, filtered through a plug of Celite, and concentrated under reduced pressure. The crude material was purified by flash column chromatography [hexanes/EtOAc (9:1)] to yield the corresponding ester.


General procedure for the acetonide protection of compound 6 and subsequent carbonylation of compound 20 to corresponding esters (27-29)



A solution of **6**¹⁰ (500 mg, 2.10 mmol) was dissolved in 2,2-dimethoxypropane (10 mL), to which was added a catalytic amount of *p*-toluenesulfonic acid. The reaction was monitored by thin layer chromatography (TLC), and was observed to be complete after 0.5 hours. The reaction mixture was concentrated under reduced pressure, diluted with EtOAc (15 mL) and washed with a saturated solution of sodium bicarbonate (2 x 3 mL) and brine (1 x 2 mL). The reaction mixture was concentrated under reduced pressure, and dissolved in a solution of THF/alcohol (9:1) (30 mL). Carbon monoxide was bubbled through the reaction mixture for 15 minutes, after which triethylamine (0.59 mL, 4.2 mmol) was added followed by solid triphenylphosphine (110 mg, 0.42 mmol) and palladium (II) acetate (47 mg, 0.21 mmol). The orange suspension was heated to 40 °C. The reaction was monitored by TLC [hexanes/EtOAc (4:1)] and consumption of the


starting material was observed after 4-6 hours. Upon cooling to room temperature, the crude reaction mixture was concentrated to dryness under reduced pressure. The residue was then dissolved in diethyl ether, filtered through a plug of Celite, and concentrated under reduced pressure. The crude material was purified by flash column chromatography [hexanes/EtOAc (9:1)] to yield the corresponding ester.

(+)-Methyl (5*S*,6*R*)-5,6-Dihydroxycyclohexa-1,3-dienecarboxylate (11) ²⁰



11: (68%); Pale yellow oil; $R_f = 0.33$ [hexanes/EtOAc (1:2)]; $[\alpha]_D^{20} = +68.8$ ($c = 0.8$, CHCl_3) [lit.²⁰ $[\alpha]_D^{23} = +71.3$ ($c = 1.6$, CHCl_3)]; IR (film) ν 3412, 2098, 1690, 1639, 1291, 820, 772 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 7.05 (d, $J = 5.3$ Hz, 1H, CH-2), 6.17 (dd, $J = 10.3, 0.6$ Hz, 1H, CH-4), 6.05 (qd, $J = 5.1, 2.2$ Hz, 1H, CH-3), 4.53 (m, 1H, CH-6), 4.45 (m, 1H, CH-5), 3.77 (s, 3H, OCH_3), ; ^{13}C NMR (75 MHz, CDCl_3) δ 167.5 (C=O), 138.6 (CH-4), 134.3 (CH-2), 128.4 (C-1), 122.6 (CH-3), 69.5 (COH-5), 64.8 (COH-6), 52.1 (OCH_3); MS (EI) m/z (%) 170 (33), 152 (61), 139 (22), 138 (96), 136 (71), 121 (100), 110 (95), 109 (66), 105 (23), 93 (42), 92 (22) 82 (57), 81 (56), 65 (59), 53 (49), 51 (22); HRMS (EI) calcd for $\text{C}_8\text{H}_{10}\text{O}_4$: 170.0579. Found: 170.0580.


(+)-Ethyl (5*S*,6*R*)-5,6-Dihydroxycyclohexa-1,3-dienecarboxylate (12) ²⁰



12: (72%); Colourless crystals; $R_f = 0.31$ [hexanes/EtOAc (1:2)]; mp 49-50 °C (pentane) [lit.²⁰ mp 48 °C (EtOAc/hexanes)]; $[\alpha]_D^{20} = +53.5$ ($c = 1.6$, CHCl_3) [lit.²⁰ $[\alpha]_D^{23} = +54.7$


($c = 3.8$, CHCl_3); IR (film) ν 3385, 2981, 2934, 1700, 1280, 1243, 1104, 1068, 825, 771 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 7.04 (d, $J = 5.3$ Hz, 1H, CH-2), 6.15 (dt, $J = 9.4$, 1.1 Hz, 1H, CH-4), 6.03 (dq, $J = 9.2$, 2.3 Hz, 1H, CH-3), 4.52 (m, 1H, CH-6), 4.44 (m, 1H, CH-5), 4.22 (q, $J = 7.0$ Hz, 2H, OCH_2), 1.28 (t, $J = 7.2$ Hz, 3H, CH_3); ^{13}C NMR (75 MHz, CDCl_3) δ 167.1 (C=O), 138.7 (CH-4), 134.1 (CH-2), 128.7 (C-1), 122.5 (CH-3), 69.8 (COH-5), 64.5 (COH-6), 60.9 (OCH_2), 14.2 (CH_3); MS (EI) m/z (%) 184 (9), 166 (20), 138 (26), 122 (33), 121 (52), 105 (100), 77 (39), 51 (21), 45 (20); HRMS (EI) calcd for $\text{C}_9\text{H}_{12}\text{O}_4$: 184.0736. Found: 184.0731; Anal. calcd for $\text{C}_9\text{H}_{12}\text{O}_4$: C, 58.69; H 6.57. Found C, 58.77; H, 6.60.

(+)-*n*-Propyl (5*S*,6*R*)-5,6-Dihydroxycyclohexa-1,3-dienecarboxylate (13)²⁰




13: (62%); Waxy solid; $R_f = 0.15$ [hexanes/EtOAc (1:1)]; $[\alpha]_D^{20} = +55.2$ ($c = 1.4$, CHCl_3) [lit.²⁰ $[\alpha]_D^{22} = +58.8$ ($c = 1.1$, CHCl_3)]; IR (film) ν 3398, 2968, 1700, 1280, 1240 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 7.08 (d, $J = 5.4$ Hz, 1H, CH-2), 6.20 (dd, $J = 9.5$, 2.5 Hz, 1H, CH-4), 6.09 (ddd, $J = 9.5$, 5.4, 2.2 Hz, 1H, CH-3), 4.58 (d, $J = 6.3$ Hz, 1H, CH-6), 4.48 (ddd, $J = 6.3$, 2.5, 2.2 Hz, 1H, CH-5), 4.16 (t, $J = 6.7$ Hz, 2H, OCH_2), 1.72 (qt, $J = 7.4$, 6.7 Hz, 2H, CH_2), 0.98 (t, $J = 7.4$ Hz, 3H, CH_3); ^{13}C NMR (75MHz, CDCl_3) δ 167.1 (C=O), 138.4 (CH-4), 133.9 (CH-2), 128.7 (C-1), 122.6 (CH-3), 69.4 (COH-5), 66.6 (OCH_2), 64.8 (COH-6), 22.0 (CH_2), 10.4 (CH_3); MS (EI) m/z (%): 198 (18), 180 (22), 138 (100), 121 (81), 110 (54), 105 (77); HRMS (EI) calcd for $\text{C}_{10}\text{H}_{14}\text{O}_4$: 198.0892. Found: 198.0892.

(+)-*i*-Propyl (5*S*,6*R*)-5,6-Dihydroxycyclohexa-1,3-dienecarboxylate (14)²⁰



14: (72%); Colourless crystals; $R_f = 0.31$ [hexanes/EtOAc (2:3)]; mp 80-82 °C (pentane) [lit.²⁰ mp 83-85 °C (EtOAc/hexanes)]; $[\alpha]_D^{22} = +66.5$ ($c = 1.0$, CHCl_3) [lit.²⁰ $[\alpha]_D^{22} = +64.7$ ($c = 1.1$, CHCl_3)]; IR (film) ν 3274, 2981, 1698, 1263, 1241 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 7.05 (ddd, $J = 5.5, 1.0, 0.5$ Hz, 1H, CH-2), 6.20 (ddt, $J = 9.6, 2.7, 0.9$ Hz, 1H, CH-4), 6.08 (ddd, $J = 9.6, 5.5, 2.2$ Hz, 1H, CH-3), 5.12 (hept, $J = 6.3$ Hz, 1H, OCH), 4.58 (dd, $J = 6.4, 0.5$ Hz, 1H, CH-6), 4.48 (br m, 1H, CH-5), 1.30 (d, $J = 6.3$ Hz, 6H, CH_3); ^{13}C NMR (75 MHz, CDCl_3) δ 166.5 (C=O), 138.2 (CH-4), 133.6 (CH-2), 128.9 (C-1), 122.63 (CH-3), 69.2 (COH-5), 68.5 (OCH), 64.9 (COH-6), 21.8 (CH_3); MS (EI) m/z (%): 198 (19), 180 (16), 156 (14), 138 (100); HRMS (EI) calcd for $\text{C}_{10}\text{H}_{14}\text{O}_4$: 198.08921. Found: 198.08896; Anal. calcd for $\text{C}_{10}\text{H}_{14}\text{O}_4$: C, 60.59; H, 7.12. Found C, 60.68; H, 7.19.


(+)-*t*-Butyl (5*S*,6*R*)-5,6-Dihydroxycyclohexa-1,3-dienecarboxylate (15)



15: (17%); White crystalline solid; $R_f = 0.31$ [hexanes/EtOAc (1:1)]; mp 88-90 °C (pentane); $[\alpha]_D^{20} = +53.3$ ($c = 0.3$, CHCl_3); IR (film) ν 3382, 2977, 2932, 1699, 1639, 1575, 1477, 1456, 1393, 1368, 1290, 1253, 1159, 1106, 1066, 1024, 993, 889, 849, 826, 783, 770 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 6.95 (d, $J = 5.6$ Hz, 1H, CH-2), 6.22 (dd, $J = 9.5, 2.8$ Hz, 1H, CH-4), 6.11 (ddd, $J = 9.5, 5.7, 1.9$ Hz, 1H, CH-3), 4.51 (dd, $J = 6.4, 4.0$ Hz, 1H, CH-6), 4.47 (m, 1H, CH-5), 1.59 (s, 9H, CH_3); ^{13}C NMR (75 MHz, CDCl_3) δ 166.4 (C=O), 137.3 (CH-4), 132.9 (CH-2), 129.8 (CH-1), 123.0 (CH-3), 87.5 (OC), 68.6 (COH-5), 65.7 (COH-6), 28.1 (CH_3); MS (EI) m/z (%): 195 (15), 194 (100), 165 (6), 162


(5), 157 (10), 156 (96), 154 (21), 152 (6); HRMS (EI) 212.1049 = C₁₁H₁₆O₄; calcd for C₁₁H₁₄O₃ [(M-18)⁺, H₂O]: 194.0943. Found: 194.0944.

(+)-Allyl (5*S*,6*R*)-5,6-Dihydroxycyclohexa-1,3-dienecarboxylate (16) ²⁰



16: (6%); Colourless crystals; *R_f* = 0.23 [hexanes/EtOAc (1:1)]; mp 44-47 °C (pentane) [lit.²⁰ mp 48-50 °C (EtOAc/hexane)]; [α]_D²⁰ = +67.4 (*c* = 0.2, CHCl₃) [lit.²⁰ [α]_D²² = +72.5 (*c* = 1.6, CHCl₃)]; IR (film) ν 3394, 1704, 1273, 1238 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 7.12 (d, *J* = 5.5 Hz, 1H, CH-2), 6.23 (ddt, *J* = 9.6, 2.7, 1.0 Hz, 1H, CH-4), 6.11 (ddd, *J* = 9.5, 5.5, 2.2 Hz, 1H, CH-3), 5.98 (ddt, *J* = 17.2, 10.4, 5.7 Hz, 1H, allyl CH), 5.37 (dt, *J* = 17.2, 1.5 Hz, 1H, allyl CH₂), 5.28 (dt, *J* = 10.4, 1.3 Hz, 1H, allyl CH₂), 4.72 (ddd, *J* = 5.7, 1.5, 1.3 Hz, 2H, OCH₂), 4.61 (br s, 1H, COH), 4.50 (br s, 1H, COH); ¹³C NMR (75 MHz, CDCl₃) δ 166.6 (C=O), 138.8 (CH-4), 134.4 (CH-2), 131.9 (allyl CH), 128.4 (C-1), 122.4 (CH-3), 118.3 (allyl CH₂), 69.6 (OCH₂), 65.5 (COH-5), 64.5 (COH-6); MS (EI) *m/z* (%): 196 (20), 178 (18), 138 (80), 121 (95), 41 (100). HRMS (EI) calcd for C₁₀H₁₂O₄: 196.07356. Found: 196.07364; Anal. calcd for C₁₀H₁₂O₄ + 1/8 H₂O: C, 60.52; H, 6.22. Found C, 60.52; H, 6.26.


(+)-Propargyl (5*S*,6*R*)-5,6-Dihydroxycyclohexa-1,3-dienecarboxylate (17) ²⁰



17: (36%); Colourless crystals; *R_f* = 0.31 [EtOAc/hexanes (3:2)]; mp 67-69 °C (pentane) [lit.²⁰ mp 70-72 °C (EtOAc/Hexanes)]; [α]_D²⁰ = +74.3 (*c* = 0.2, CHCl₃) [lit.²⁰ [α]_D²² =


+88.20 ($c = 1.6$, CHCl_3); IR(film) ν 3385, 3291, 1707, 1270, 1234 cm^{-1} ; ^1H NMR (300 MHz, acetone- d_6) δ 7.15 (dd, $J = 5.7, 0.8$ Hz, 1H, CH-2), 6.25 (dd, $J = 9.7, 2.7$ Hz, 1H, CH-4), 6.12 (ddd, $J = 9.8, 5.6, 2.2$ Hz, 1H, CH-3), 4.82 (d, $J = 2.5$ Hz, 2H, OCH_2), 4.62 (dd, $J = 6.8, 4.7$ Hz, 1H, CH-6), 4.54 (m, 1H, CH-5), 2.50 (t, $J = 2.5$ Hz, 1H, CH); ^{13}C NMR (75 MHz, acetone- d_6) δ 167.2 (C=O), 142.5 (CH-4), 136.3 (CH-2), 131.1 (C-1), 123.5 (CH-3), 80.0 (propargyl C), 77.3 (propargyl CH), 72.5 (COH-5), 65.5 (COH-6), 53.4 (OCH_2); MS (EI) m/z (%): 194 (7), 176 (28), 138 (47), 121 (100); HRMS (EI) calcd for $\text{C}_{10}\text{H}_{10}\text{O}_4$: 194.0579. Found: 194.0581; Anal. calcd for $\text{C}_{10}\text{H}_{10}\text{O}_4$: C, 61.85; H, 5.19. Found: C, 62.08; H, 5.18.

(+)-Benzyl (5*S*,6*R*)-5,6-Dihydroxycyclohexa-1,3-dienecarboxylate (18)




18: (10%); Pale yellow oil; $R_f = 0.30$ [hexanes/EtOAc (1:1)]; $[\alpha]_D^{20} = +48.8$ ($c = 0.2$, CHCl_3); IR (film) ν 3390, 2959, 1704, 1639, 1575, 1498, 1455, 1395, 1260, 1164, 1104, 1066, 1027, 995, 915, 811, 757, 697; ^1H NMR (600 MHz, CDCl_3) δ 7.38 (d, $J = 4.5$ Hz, 1H, C_6H_5), 7.35 (m, 4H, C_6H_5), 7.12 (d, $J = 5.6$ Hz, 1H, CH-2), 6.23 (dd, $J = 9.7, 2.8$ Hz, 1H, CH-4), 6.12-6.09 (m, 1H, CH-3), 5.25 (s, 2H, OCH_2), 4.62 (m, 1H, CH-6), 4.49 (m, 1H, CH-5); ^{13}C NMR (150 MHz, CDCl_3) δ 166.8 (C=O), 138.5 (CH-4), 135.7 (CH-2), 134.3 (benzyl C), 128.7 (C-1), 128.4 (benzyl CH), 128.3 (benzyl CH), 128.2 (benzyl CH), 122.8 (CH-3), 68.9 (COH-5), 66.8 (OCH_2), 65.2 (COH-6); MS (EI) m/z (%): 246 (13), 244 (58), 238 (24), 228 (28), 221 (13), 220 (100), 213 (19), 212 (99), 210 (12), 207 (12), 204 (17), 201 (10), 200 (49), 199 (16), 197 (13), 195 (15), 194 (36), 192 (12), 183 (15), 182 (14), 181 (19), 179 (15), 172 (12), 169 (10), 168 (11), 167 (30), 166 (14), 165 (20), 159 (11), 157 (22), 156 (31), 155 (45), 154 (13), 153 (20), 152 (18), 151 (15); HRMS (EI) 246.0892 = $\text{C}_{14}\text{H}_{14}\text{O}_4$; calcd for $\text{C}_{14}\text{H}_{12}\text{O}_3$ [(M-18) $^+$, H_2O]: 228.0786. Found: 228.0787.

(+)-Methyl (3a*R*,7a*S*)-2,2-Dimethyl-3a,7a-dihydrobenzo[*d*][1,3]dioxole-4-carboxylate
(22)^{19, 25d}



22: (68%); Colourless oil; $R_f = 0.45$ [hexanes/EtOAc (4:1)]; $[\alpha]_D = +88.5$ ($c = 0.2$, CHCl_3); IR (film) ν 2988, 2952, 1715, 1651, 1589, 1437, 1371, 1260, 1160, 1108, 1081, 1030, 881, 864, 762, 707, 631, 522 cm^{-1} ; $^1\text{H NMR}$ (300 MHz, CDCl_3) 7.14 (m, 1H, CH-5), 6.11 (m, 2H, CH-6/CH-7), 4.94 (d, $J = 8.4$ Hz, 1H, CO-3a), 4.87 (dd, $J = 8.5, 1.9$ Hz, 1H, CO-7a), 3.83 (s, 3H, OCH_3), 1.46 (s, 3H, CH_3), 1.40 (s, 3H, CH_3); $^{13}\text{C NMR}$ (150 MHz, CDCl_3) δ 166.7 (C=O), 134.0 (CH-6), 133.9 (CH-5), 126.1 (C-4), 121.3 (CH-7), 105.6 (OCO-2), 72.5 (CO-7a), 68.2 (CO-3a), 52.0 (OCH_3), 26.7 (CH_3), 25.1 (CH_3); MS (EI) m/z (%) 195 (68), 163 (11), 153 (100), 152 (39), 121 (90), 120 (16), 109 (57), 105 (21), 94 (21), 93 (27), 92 (18), 79 (12), 77 (32), 65 (44), 63 (10), 59 (37), 51 (11); HRMS (EI) 210.0892 = $\text{C}_{11}\text{H}_{14}\text{O}_4$; calcd $\text{C}_{10}\text{H}_{11}\text{O}_4$ [(M-15)⁺, CH_3]: 195.0657. Found: 195.0655.


(+)-Ethyl (3a*R*,7a*S*)-2,2-Dimethyl-3a,7a-dihydrobenzo[*d*][1,3]dioxole-4-carboxylate
(23)²⁰



23: (73%); Colourless oil; $R_f = 0.56$ [hexanes/EtOAc (1:1)]; $[\alpha]_D^{20} = +76.2$ ($c = 1.3$, CHCl_3) [lit.²⁰ $[\alpha]_D^{23} = +74.6$ ($c = 4.0$, CHCl_3)]; IR (film) ν 3018, 2987, 2936, 1712, 1651, 1425, 1380, 1259, 1155, 1031, 917, 856, 697, 667, 512 cm^{-1} ; $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 7.06 (dd, $J = 5.6, 0.8$ Hz, 1H, CH-5), 6.24 (dd, $J = 9.5, 2.8$, 1H, CH-6), 6.13 (ddd, $J = 9.9, 5.7, 2.1$, 1H, CH-7), 4.62 (d, $J = 6.4$ Hz, 1H, CH-3a), 4.50 (m, 1H, CH-7a),


4.29 (q, $J = 7.2$, 2H, OCH₂), 1.35 (t, $J = 7.2$ Hz, 3H, CH₃); ¹³C NMR (75 MHz, CDCl₃) δ 166.2 (C=O), 142.3 (CH-6), 130.0 (CH-5), 126.4 (C-4), 121.3 (CH-7), 108.5 (OCO-2), 72.6 (OCH₂), 70.4 (CO-7a), 60.5 (CO-3a), 26.2 (CH₃), 25.1 (CH₃), 14.2 (CH₃); MS (EI) m/z (%): 211 (77), 181 (15), 169 (17), 123 (100), 105 (17), 95 (13), 83 (11), 79 (76), 67 (14), 59 (10), 55 (11), 43 (82), 41 (14); HRMS (EI) 224.1049 = C₁₂H₁₆O₄; calcd C₁₁H₁₃O₄ [(M-15)⁺, CH₃]: 211.0970. Found: 211.0969; Anal. calcd for C₁₂H₁₆O₄: C, 64.27; H, 7.19. Found C, 64.52; H, 7.08.

(+)-*n*-Propyl (3a*R*,7a*S*)-2,2-Dimethyl-3a,7a-dihydrobenzo[*d*][1,3]dioxole-4-carboxylate (24)




24: (68%); Clear colourless oil; $R_f = 0.46$ [hexanes/EtOAc (4:1)]; $[\alpha]_D^{20} = +72.6$ ($c = 1.2$, CHCl₃); IR (film) ν 2974, 2937, 1713, 1589, 1460, 1379, 1370, 1256, 1160, 1107, 1080, 1052, 1027, 863, 705 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 7.16-7.14 (m, 1H, CH-5), 6.11 (m, 2H, CH-6/CH-7), 4.95 (d, $J = 8.3$ Hz, 1H, CH-7a), 4.87 (dd, $J = 8.3, 1.4$ Hz, 1H, CH-3a), 4.19 (t, $J = 6.6$ Hz, 2H, OCH₂), 1.74 (m, 2H, CH₂), 1.46 (s, 3H, CH₃), 1.41 (s, 3H, CH₃), 1.00 (t, $J = 7.4$ Hz, 3H, CH₃); ¹³C NMR (75 MHz, CDCl₃) δ 166.2 (C=O), 133.8 (CH-6), 133.6 (CH-5), 126.4 (C-4), 121.3 (CH-7), 105.5 (OCO-2), 72.6 (CO-7a), 68.2 (CO-3a), 66.4 (OCH₂), 26.7 (CH₃), 25.0 (CH₃), 22.0 (CH₂), 10.5 (CH₃); MS (EI) m/z (%) 223 (27), 181 (72), 180 (18), 179 (17), 163 (11), 139 (100), 138 (42), 137 (18), 122 (11), 121 (69), 120 (15), 110 (18), 105 (21), 95 (65), 94 (18), 93 (15), 82 (12), 77 (24), 66 (11), 65 (28), 58 (49); HRMS (EI) 238.1205 = C₁₃H₁₈O₄; calcd C₁₂H₁₅O₄ [(M-15)⁺, CH₃]: 223.0970. Found: 223.0968.

(+)-*i*-Propyl (3a*R*,7a*S*)-2,2-Dimethyl-3a,7a-dihydrobenzo[*d*][1,3]dioxole-4-carboxylate (25)



25: (76%); Clear colourless oil; $R_f = 0.51$ [hexanes/EtOAc (4:1)]; $[\alpha]_D^{20} = +94.8$ ($c = 0.1$, CHCl_3); IR (film) ν 2983, 2935, 1710, 1589, 1455, 1372, 1261, 1160, 1106, 1027, 927, 862, 803, 706 cm^{-1} ; $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 7.12 (m, 1H, CH-5), 6.10 (m, 2H, CH-6/CH-7), 5.16 (hept, $J = 6.4$, 1H, OCH), 4.94 (d, $J = 8.3$ Hz, 1H, CH-3a), 4.87 (dd, $J = 8.3$, 1.4 Hz, 1H, CH-7a), 1.47 (s, 3H, CH_3), 1.41 (s, 3H, CH_3), 1.31 (d, $J = 6.3$, 6H, CH_3); $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 165.6 (C=O), 133.7 (CH-6), 133.4 (CH-5), 126.7 (C-4), 121.3 (CH-7), 105.5 (OCO-2), 72.6 (CO-7a), 68.2 (OCH), 68.1 (CO-3a), 26.7 (CH_3), 25.0 (CH_3), 21.9 (CH_3), 21.9 (CH_3); MS (EI) m/z (%) 223 (19), 181 (68), 180 (19), 179 (19), 139 (100), 138 (55), 137 (20), 122 (14), 121 (96), 120 (22), 110 (17), 105 (18), 95 (49), 94 (21), 93 (19), 92 (12), 82 (18), 77 (24), 66 (15), 65 (35), 59 (16); HRMS (EI) 238.1205 = $\text{C}_{13}\text{H}_{18}\text{O}_4$; calcd $\text{C}_{12}\text{H}_{15}\text{O}_4$ [(M-15) $^+$, CH_3]; 223.0970. Found: 223.0966.


(+)-*t*-Butyl (3aR,7aS)-2,2-Dimethyl-3a,7a-dihydrobenzo[d][1,3]dioxole-4-carboxylate (26)



26: (10%); Clear colourless oil; $R_f = 0.63$ [hexanes/EtOAc (4:1)]; $[\alpha]_D^{20} = +81.3$ ($c = 0.6$, CHCl_3); IR (film) ν 2981, 2933, 1707, 1589, 1456, 1368, 1275, 1255, 1160, 1109, 1050, 1025, 905, 848, 704 cm^{-1} ; $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 7.06 (m, 1H, CH-5), 6.08 (m, 2H, CH-6/CH-7), 4.87 (d, $J = 8.2$ Hz, 1H, CH-3a), 4.85 (d, $J = 8.3$, 1H, CH-7a), 1.54 (s, 9H, CH_3), 1.46 (s, 3H, CH_3), 1.41 (s, 3H, CH_3); $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 165.4 (C=O), 133.5 (CH-6), 133.1 (CH-5), 127.6 (C-4), 121.3 (CH-7), 105.5 (OCO-2), 81.0 (OC), 72.8 (CO-7a), 68.2 (CO-3a), 28.2 (CH_3), 26.7 (CH_3), 25.0 (CH_3); MS (EI) m/z (%) 181 (25), 179 (14), 139 (46), 138 (40), 121 (46), 95 (19), 94 (21), 93 (13), 77 (14), 65


(24), 57 (100); HRMS (EI) 252.1361 = C₁₄H₂₀O₄; calcd C₁₃H₁₇O₄ [(M-15)⁺, CH₃]: 237.1122. Found: 237.1127.

(+)-Allyl (3a*R*,7a*S*)-2,2-Dimethyl-3a,7a-dihydrobenzo[*d*][1,3]dioxole-4-carboxylate (27)




27: (27%); Clear colourless oil; $R_f = 0.65$ [hexanes/EtOAc (4:1)]; $[\alpha]_D^{20} = +79.3$ ($c = 0.2$, CHCl₃); IR (film) ν 2987, 2935, 1715, 1649, 1589, 1455, 1404, 1371, 1252, 1161, 1109, 1029, 993, 923, 863, 706 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 7.18 (m, 1H, CH-5), 6.12 (m, 2H, CH-6/CH-7), 5.98 (m, 1H, allyl CH), 5.38 (dq, $J = 17.4, 1.7$ Hz, 1H, allyl CH₂), 5.26 (dq, $J = 10.6, 1.6$ Hz, 1H, allyl CH₂), 4.96 (d, $J = 8.5$ Hz, 1H, CH-3a), 4.88 (dd, $J = 8.5, 2.1$ Hz, 1H, CH-7a), 4.74 (dt, $J = 5.5, 1.5$ Hz, 2H, OCH₂), 1.46 (s, 3H, CH₃), 1.41 (s, 3H, CH₃); ¹³C NMR (75 MHz, CDCl₃) δ 165.8 (C=O), 134.0 (CH-6), 134.0 (CH-5), 132.2 (allyl CH₂), 126.1 (C-4), 121.3 (CH-7), 118.0 (allyl CH), 105.6 (OCO-2), 72.5 (CO-7a), 68.1 (CO-3a), 65.4 (OCH₂), 26.7 (CH₃), 25.0 (CH₃); MS (EI) m/z (%) 221 (22), 220 (14), 179 (57), 163 (13), 161 (30), 137 (15), 135 (17), 122 (14), 121 (100), 109 (11), 107 (23), 105 (32), 94 (15), 93 (18), 77 (25), 65 (31); HRMS (EI) 236.1049 = C₁₃H₁₆O₄; calcd C₁₂H₁₃O₄ [(M-15)⁺, CH₃]: 221.0814. Found: 221.0810.

(+)-Propargyl (3a*R*,7a*S*)-2,2-Dimethyl-3a,7a-dihydrobenzo[*d*][1,3]dioxole-4-carboxylate (28)²⁰




28: (20%); Colourless oil; $R_f = 0.54$ [hexanes/EtOAc (4:1)]; $[\alpha]_D^{20} = +110.6$ ($c = 0.2$, CHCl_3) [lit.²⁰ $[\alpha]_D^{22} = +112.7$ ($c = 1.3$, CHCl_3)]; IR (film) ν 2987, 2935, 1718, 1030 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 7.22 (dd, $J = 5.3, 1.1$ Hz, 1H, CH-5), 6.14 (m, 2H, CH-6/CH-7), 4.95 (d, $J = 8.4$ Hz, 1H, CH-3a), 4.89 (dd, $J = 8.4, 2.4$ Hz, 1H, CH-7a), 4.84 (dd, $J = 2.5, 1.0$ Hz, 2H, OCH_2), 2.50 (t, $J = 2.5$ Hz, 1H, propargyl CH), 1.47 (s, 3H, CH_3), 1.41 (s, 3H, CH_3); ^{13}C NMR (75 MHz, CDCl_3) δ 165.3 (C=O), 134.8 (CH-6), 134.4 (CH-5), 125.5 (C-4), 121.2 (CH-7), 105.7 (OCO-2), 77.7 (propargyl C), 74.9 (propargyl CH), 71.8 (CO-7a), 68.0 (CO-3a), 52.3 (OCH_2), 26.7 (CH_3), 25.0 (CH_3); MS (EI) m/z (%) 219 (42), 177 (41), 163 (17), 121 (83), 43 (100); HRMS (EI) calcd for $\text{C}_{12}\text{H}_{11}\text{O}_4$: 219.0657. Found: 219.0659; Anal. calcd for $\text{C}_{13}\text{H}_{14}\text{O}_4$: C, 66.66; H, 6.02. Found: C, 66.68; H, 6.08.

(+)-Benzyl (3aR,7aS)-2,2-Dimethyl-3a,7a-dihydrobenzo[d][1,3]dioxole-4-carboxylate (29)



29: (70%); Clear colourless oil; $R_f = 0.53$ [hexanes/EtOAc (4:1)]; $[\alpha]_D^{20} = +75.8$ ($c = 1.5$, CHCl_3); IR (film) ν 3034, 2987, 2935, 1712, 1588, 1455, 1371, 1253, 1161, 1108, 1028, 864, 737, 698 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ 7.39 (m, 5H, C_6H_5), 7.19 (m, 1H, CH-5), 6.12 (m, 2H, CH-6/CH-6), 5.28 (s, 2H, OCH_2), 4.98 (d, $J = 8.4$ Hz, 1H, CH-3a), 4.88 (dd, $J = 8.4, 2.2$ Hz, 1H, CH-7a), 1.48 (s, 3H, CH_3), 1.42 (s, 3H, CH_3); ^{13}C NMR (75 MHz, CDCl_3) δ 166.0 (C=O), 136.0 (CH-6), 134.2 (CH-5), 134.1 (C_6H_5), 128.5 (C_6H_5), 128.2 (C_6H_5), 128.1 (C_6H_5), 126.1 (C-4), 121.3 (CH-7), 105.6 (OCO-2), 72.5 (CO-7a), 68.2 (CO-3a), 66.5 (OCH_2), 26.7 (CH_3), 25.1 (CH_3); MS (EI) m/z (%) 105 (15), 91 (100), 77 (14), 65 (25), 58 (11), 52 (15); HRMS (EI) 286.1205 = $\text{C}_{17}\text{H}_{18}\text{O}_4$; calcd $\text{C}_{11}\text{H}_{13}\text{O}_4$ [(M-15)⁺, CH_3]: 271.0965. Found: 271.0966.


(+)-(3a*S*,5a*S*,6*S*,6a*S*,9a*S*,10*R*,10a*R*,10b*S*)-4,6-Diiodo-2,2,8,8-tetramethyl-3a,5a,6,6a,9a,10,10a,10b-octahydro-6,10-ethenonaphtho[1,2-*d*:6,7-*d'*]bis([1,3]dioxole) (**30**)



Acetonide **20**²⁹ was dissolved in *o*-xylene and heated to reflux for 40 hours. The solution was concentrated under reduced pressure and purified via flash column chromatography [hexanes/EtOAc (4:1)] to obtain 0.19 g (38%) of **2** as a white solid.

30: R_f = 0.39 [hexanes/EtOAc (4:1)]; mp 220-224 °C (EtOAc/pentane); $[\alpha]_D^{20}$ = +106.5 (c = 1.0, CHCl₃); IR (film) ν 2984, 2933, 2898, 1455, 1380, 1280, 1262, 1236, 1225, 1209, 1160, 1082, 1068, 1012 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 6.89 (d, J = 3.7 Hz, 1H, CH-5), 6.25 (d, J = 8.6 Hz, 1H, CH-11), 5.79 (t, J = 7.3 Hz, 1H, CH-12), 4.49 (d, J = 7.2 Hz, 1H, CH-6a), 4.38 (dd, J = 7.2, 3.6 Hz, 1H, CH-9a), 4.18 (d, J = 4.6 Hz, 1H, CH-3a), 4.15 (d, J = 4.1 Hz, 1H, CH-10b), 2.91 (m, 1H, CH-10), 2.71 (dd, J = 8.7, 3.6 Hz, 1H, CH-5a), 2.49 (d, J = 9.2 Hz, 1H, CH-10a), 1.47 (s, 3H, CH₃), 1.40 (s, 3H, CH₃), 1.38 (s, 3H, CH₃), 1.36 (s, 3H, CH₃); ¹³C NMR (150 MHz, CDCl₃) δ 140.1 (CH-5), 139.0 (CH-11), 128.7 (CH-12), 109.3 (OCO-2), 108.7 (OCO-8), 103.9 (C-4), 84.7 (CO-6a), 79.1 (CO-9a), 78.6 (CO-3a), 75.2 (CO-10b), 48.3 (C-6), 45.6 (CH-5a), 38.4 (CH-10), 35.2 (CH-10a), 27.9 (CH₃), 26.7 (CH₃), 25.5 (CH₃), 25.1 (CH₃); MS (EI) m/z (%) 122 (11), 107 (14), 105 (11), 104 (43), 93 (11), 91 (26), 79 (23), 78 (10), 77 (23), 75 (27), 70 (12), 69 (11), 61 (14), 57 (18), 55 (15), 45 (19), 43 (100), 42 (11), 41 (18), 39 (15); HRMS (EI) calcd for C₁₈H₂₂O₄: 555.9607. Found: 555.9602; Anal. calcd for C₁₈H₂₂I₂O₄: C, 38.87; H, 3.99. Found: C, 39.14; H, 4.04.


(+)-(3aR,5aR,6S,6aR,9aS,10R,10aS,10bS)-Dimethyl 2,2,8,8-tetramethyl-3a,5a,6,6a,9a,10,10a,10b-octahydro-6,10-ethenonaphtho[1,2-d:6,7-d']bis([1,3]dioxole)-4,6-dicarboxylate (**31**)



Acetonide **22**^{19, 25d} was dissolved in *o*-xylene and heated to reflux for 24 hours. The solution was concentrated under reduced pressure and purified via flash column chromatography [hexanes/EtOAc (6:1)] to obtain **34** mg (42%) of **31** as white powdery solid.

31: $R_f = 0.33$ [hexanes/EtOAc (3:1)]; mp 180-183 °C (pentane); $[\alpha]_D^{20} = +50.3$ ($c = 0.4$, CHCl₃); IR (film) ν 2932, 1737, 1436, 1379, 1283, 1262, 1210, 1164, 1060, 882, 804, 742 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 6.45 (d, $J = 8.3$ Hz, 1H, CH-5), 6.20 (t, $J = 7.2$ Hz, 1H, CH-11), 5.40 (t, $J = 2.6$ Hz, 1H, CH-12), 4.63 (dd, $J = 7.2, 1.4$ Hz, 1H, CH-6a), 4.40 (dd, $J = 7.3, 3.2$ Hz, 1H, CH-9a), 4.29 (t, $J = 7.6$ Hz, 1H, CH-3a), 3.90 (s, 3H, OCH₃), 3.79 (s, 3H, OCH₃), 3.63 (t, $J = 8.2$, 1H, CH-10b), 3.37 (m, 1H, CH-10), 3.11 (dt, $J = 7.4, 2.5$ Hz, 1H, CH-5a), 1.94 (dd, $J = 8.3, 1.9$ Hz, 1H, CH-10a), 1.51 (s, 3H, CH₃), 1.35 (s, 6H, CH₃), 1.30 (s, 3H, CH₃); ¹³C NMR (150 MHz, CDCl₃) δ 173.0 (C=O), 171.2 (C=O), 138.8 (CH-5), 129.7 (CH-11), 128.5 (CH-12), 117.8 (C-4), 110.0 (OCO-2), 109.9 (OCO-8), 79.0 (CO-6a), 78.4 (CO-9a), 77.3 (CO-3a), 56.3 (C-6), 52.6 (OCH₃), 52.5 (OCH₃), 48.9 (CH-5a), 42.6 (CH-10), 38.3 (CH-10a), 27.2 (CH₃), 25.4 (CH₃), 25.0 (CH₃), 24.6 (CH₃); MS (EI) m/z (%) 213 (8), 157 (6), 131 (6), 121 (7), 100 (13), 97 (6), 95 (6), 83 (6), 81 (4), 77 (7), 71 (6), 70 (5), 69 (15), 61 (5), 59 (5), 58 (100), 57 (12), 55 (9); HRMS (EI) calcd for C₂₂H₂₈O₈: 420.1784. Found: 420.1801; Anal. calcd for C₂₂H₂₈O₈: C, 62.85; H, 6.71. Found: C, 63.10; H, 6.79.

(+)-(3a*R*,5a*R*,6*S*,6a*R*,9a*S*,10*R*,10a*S*,10b*S*)-Diethyl 2,2,8,8-tetramethyl-3a,5a,6,6a,9a,10,10a,10b-octahydro-6,10-ethenonaphtho[1,2-*d*:6,7-*d'*]bis([1,3]dioxole)-4,6-dicarboxylate (**32**)



A solution of acetonide **23**²⁰ was dissolved in *o*-xylene and heated to reflux for 40 hours. The solution was concentrated under reduced pressure and purified via flash column chromatography [hexanes/EtOAc (4:1)] to obtain 0.34 g (68%) of **32** as pale yellow solid.

32: R_f = 0.24 [hexanes/EtOAc (4:1)]; mp 91-93 °C (pentane); $[\alpha]_D^{20}$ = +47.8 (c = 1.0, CHCl₃); IR (film) ν 2984, 2937, 1721, 1458, 1380, 1262, 1221, 1163, 1072, 1026 cm⁻¹; ¹H NMR (600 MHz, CDCl₃) δ 6.43 (d, J = 3.8 Hz, 1H, CH-5), 6.38 (d, J = 8.8 Hz, 1H, CH-11), 6.04 (t, J = 7.0 Hz, 1H, CH-12), 4.60 (d, J = 7.0 Hz, 1H, CH-6a), 4.58 (d, J = 4.8 Hz, 1H, CH-9a), 4.43 (dd, J = 7.0, 3.3 Hz, 1H, CH-3a), 4.37 (q, J = 13.9 Hz, 2H, OCH₂), 4.22 (m, 2H, OCH₂), 4.16 (dd, J = 4.6, 1.9 Hz, 1H, CH-10b), 3.01 (m, 1H, CH-10), 2.95 (dd, J = 9.0, 3.3 Hz, 1H, CH-5a), 2.32 (d, J = 9.1, 1H, CH-10a), 1.35 (s, 3H, CH₃), 1.33 (t, J = 7.1 Hz, 3H, CH₃), 1.29 (s, 3H, CH₃), 1.28 (s, 3H, CH₃), 1.27 (s, 3H, CH₃), 1.26 (s, 3H, CH₃); ¹³C NMR (150 MHz, CDCl₃) δ 171.5 (C=O), 165.9 (C=O), 136.5 (CH-5), 131.5 (CH-11), 130.2 (CH-12), 128.8 (C-4), 109.7 (OCO-2), 108.2 (OCO-8), 80.7 (CO-6a), 78.3 (CO-9a), 76.9 (CO-3a), 69.2 (CO-10b), 61.5 (OCH₂), 60.7 (OCH₂), 53.9 (C-6), 40.4 (CH-10), 38.6 (CH-5a), 34.9 (CH-10a), 28.1 (CH₃), 26.5 (CH₃), 25.4 (CH₃), 25.1 (CH₃), 14.2 (CH₃), 14.2 (CH₃); MS (EI) m/z (%) 433 (22), 390 (27), 375 (22), 287 (22), 286 (25), 285 (65), 273 (14), 272 (27), 269 (53), 259 (20), 258 (17), 257 (26), 245 (17), 244 (22), 241 (32), 229 (26), 228 (14), 227 (100), 217 (14), 213 (27); HRMS (EI) 448.2097 = C₂₄H₃₂O₈; calcd C₂₃H₂₉O₈ [(M-15)⁺, CH₃]: 433.1857. Found: 433.1857; Anal. calcd for C₂₄H₃₂O₈: C, 64.27; H, 7.19. Found C, 63.99; H, 7.30.

References

- 1) (a) D. T. Gibson, J. R. Koch and R. E. Kallio, *Biochemistry* **1968**, *7*, 2653; (b) D. T. Gibson, J. R. Koch, C. L. Schuld and R. E. Kallio, *Biochemistry* **1968**, *7*, 3795; (c) D. T. Gibson, M. Hensley, H. Yoshioka and T. J. Mabry, *Biochemistry* **1970**, *9*, 1626; (d) H. Ziffer, K. Kabuto, D. T. Gibson, V. M. Kobal and D. M. Jerina, *Tetrahedron* **1977**, *33*, 2491.
- 2) R. A. Johnson, *Org. Reactions* **2004**, *63*, 117.
- 3) (a) S. E. Lewis, *Chem. Commun.* **2014**, *50*, 2821; (b) D. J.-Y. D. Bon, B. Lee, M. G. Banwell and I. A. Cade, *Chim. Oggi.* **2012**, *30* (No.5, Chiral Technologies Supplement), 22; (c) T. Hudlicky and J. W. Reed, *Synlett* **2009**, 685; (d) T. Hudlicky and J. W. Reed, *Chem. Soc. Rev.* **2009**, *38*, 3117; (e) D. R. Boyd and T. D. H. Bugg, *Org. Biomol. Chem.* **2006**, *4*, 181; (f) M. G. Banwell, A. J. Edwards, K. A. Harfoot, K. A. Jolliffe, M. D. McLeod, K. J. McRae, S. G. Stewart and M. Vogtle, *Pure Appl. Chem.* **2003**, *75*, 223; (g) D. R. Boyd and N. D. Sharma, *J. Mol. Catal. B* **2002**, *19-20*, 31; (h) D. R. Boyd, N. D. Sharma and C. C. R. Allen, *Curr. Opin. Biotechnol.* **2001**, *12*, 564; (i) T. Hudlicky, D. Gonzalez and D. T. Gibson, *Aldrichim. Acta.* **1999**, *32*, 35; (j) D. R. Boyd and G. N. Sheldrake, *Nat. Prod. Rep.* **1998**, *15*, 309; (k) J. W. Reed and T. Hudlicky, *In Advances in Asymmetric Synthesis.* (Hassner, A., Ed.). JAI Press: Greenwich, CT. **1995**; (l) S. M. Brown and T. Hudlicky, *In Organic Synthesis: Theory and Applications.* (Hudlicky, T., Ed.). JAI Press: Greenwich, CT. **1993**; (m) H. A. J. Carless, *Tetrahedron Asymm.* **1992**, *3*, 795; (n) D. A. Widdowson, D. W. Ribbons and D. D. Thomas, *Janssen Chim. Acta.* **1990**, *8*, 3.
- 4) G. J. Zylstra and D. T. Gibson, *J. Biol. Chem.* **1989**, *264*, 14940.
- 5) M. A. Endoma, V. P. Bui, J. Hansen, and T. Hudlicky, *Org. Process Res. Dev.* **2002**, *6*, 525.
- 6) T. Hudlicky, M. Stabile, D. T. Gibson, and G. M. Whited, *Org. Synth.* **1999**, *76*, 77.
- 7) (a) H. Ziffer, D. M. Jerina, D. T. Gibson and V. M. Bobal, *J. Am. Chem. Soc.*, **1973**, *95*, 4048; (b) V. M. Kobal, D. T. Gibson, R. E. Davis, and A. Garza, *J. Am. Chem. Soc.* **1973**, *95*, 4420.

- 8) T. Hudlicky, H. Luna, G. Barbieri and L. D. Kwart, *J. Am. Chem. Soc.* **1988**, *110*, 4735.
- 9) D. R. Boyd, M. R. J. Dorrity, M. V. Hand, J. F. Malone, N. D. Sharma, H. Dalton, D. J. Gray and G. N. Sheldrake, *J. Am. Chem. Soc.* **1991**, *113*, 666.
- 10) D. R. Boyd, N. D. Sharma, B. Byrne, M. V. Hand, J. F. Malone, G. N. Sheldrake, J. Blacker and H. Dalton, *J. Chem. Soc., Perkin Trans. 1* **1998**, 1935.
- 11) T. Hudlicky, M. R. Stabile, D. T. Gibson and G. M. Whited, *Org. Synth.* **1999**, *76*, 77.
- 12) T. Hudlicky, J. D. Price, F. Rulin and T. Tsunoda, *J. Am. Chem. Soc.* **1990**, *112*, 9439.
- 13) D. R. Boyd, M. V. Hand, N. D. Sharma, J. Chima, H. Dalton and G. N. Sheldrake, *J. Chem. Soc., Chem. Comm.* **1991**, 1630.
- 14) D. R. Boyd, N. D. Sharma, S. A. Barr, H. Dalton, J. Chima, G. M. Whited and R. Seemayer, *J. Am. Chem. Soc.* **1994**, *116*, 1147.
- 15) T. Hudlicky, J. G. Seoane and T. Pettus, *J. Org. Chem.* **1989**, *54*, 4219.
- 16) T. Hudlicky, E. E. Boros and C. H. Boros, *Tetrahedron: Asymm.* **1993**, *4*, 1365.
- 17) T. Hudlicky, M. A. A. Endoma and G. Butora, *J. Chem. Soc., Perkin Trans. 1* **1996**, 2187.
- 18) M. R. Stabile, T. Hudlicky and M. L. Meisels, *Tetrahedron: Asymm.* **1995**, *6*, 537.
- 19) A. J. Blacker, R. J. Booth, G. M. Davies and J. K. Sutherland, *J. Chem. Soc., Perkin Trans. 1* **1995**, 2861.
- 20) F. Fabris, J. Collins, B. Sullivan, H. Leisch, and T. Hudlicky, *Org. Biomol. Chem.* **2009**, *7*, 2619.
- 21) (a) L. Werner, A. Machara, B. Sullivan, I. Carrera, M. Moser, D. R. Adams, T. Hudlicky and J. Andraos, *J. Org. Chem.* **2011**, *76*, 10050; (b) L. Werner, A. Machara and T. Hudlicky, *Adv. Synth. Catal.* **2010**, *352*, 195; (c) B. Sullivan, I. Carrera, M. Drouin and T. Hudlicky, *Angew. Chem. Int. Ed.* **2009**, *48*, 4229.
- 22) V. P. Bui, M. Nguyen, J. Hansen, J. Baker and T. Hudlicky, *Can. J. Chem.* **2002**, *80*, 708.
- 23) V. Semak, T. A. Metcalf, M. A. A. Endoma- Arias, P. Mach and T. Hudlicky, *Org. Biomol. Chem.* **2012**, *10*, 4407.

- 24) J. Froese, M. A. A. Endoma-Arias and T. Hudlicky, *Org. Process Res. Dev.* **2014**, *18*, 801.
- 25) (a) D. R. Boyd, N. D. Sharma, M. Kaik, P. B. A. McIntyre, P. J. Stevenson and C. C. R. Allen, *Org. Biomol. Chem.* **2012**, *10*, 2774; (b) D. R. Boyd, M. Bell, K. S. Dunne, B. Kelly, P. J. Stevenson, J. F. Malone and C. C. R. Allen, *Org. Biomol. Chem.* **2012**, *10*, 1388; (c) D. R. Boyd, N. D. Sharma, M. Kaik, M. Bell, M. V. Berberian, P. B. A. McIntyre, B. Kelly, C. Hardacre, P. J. Stevenson and C. C. R. Allen, *Org. Biomol. Chem.* **2011**, *13*, 2455; (d) D. R. Boyd, N. D. Sharma, N. I. Bowers, G. B. Coen, J. F. Malone, C. R. O'Dowd, P. J. Stevenson and C. C. R. Allen, *Org. Biomol. Chem.* **2010**, *8*, 1415.
- 26) (a) T. A. Reekie, M. G. Banwell and A. C. Willis, *J. Org. Chem.* **2013**, *78*, 7100; (b) X. Ma, M. G. Banwell and A. C. Willis, *J. Nat. Prod.* **2013**, *76*, 1514.
- 27) (a) C. A. Pittol, R. J. Pryce, S. M. Roberts, G. Ryback, V. Sik and J. O. Williams *J. Chem. Soc., Perkin Trans. 1* **1989**, 1160; (b) S. V. Ley, A. J. Redgrave, S. C. Taylor, S. Ahmed and D. W. Ribbons, *Synlett* **1991**, 741; (c) T. Hudlicky, E. E. Boros, H. F. Olivo, J. S. Merola, *J. Org. Chem.* **1992**, *57*, 1026; (d) T. Hudlicky and C. H. Boros, *Tetrahedron Lett.* **1993**, *34*, 2557.
- 28) C. M. Clouthier and J. N. Pelletier. *Chem. Soc. Rev.* **2012**, *41*, 1585.
- 29) D. R. Boyd, N. D. Sharma, N. M. Llamas, J. F. Malone, C. R. O'Dowd and C. C. R. Allen, *Org. Biomol. Chem.* **2005**, *3*, 1953.